Washington, D.C. – Despite recent reports indicating a decline in overall drug overdose deaths across the United States, a troubling trend has emerged: fatalities involving multiple substances, often referred to as polysubstance overdoses, are on the rise. In 2022, data revealed that over half of the synthetic opioid overdose victims also had stimulants present in their systems. This highlights a shifting drug landscape that has serious implications for public health.
In the years leading up to 2020, opioid-related deaths involving alcohol surged by more than 40%. New and potent substances, including the animal tranquilizers xylazine and medetomidine, are increasingly appearing in illicit drug supplies. A concerning spike was seen between January 2019 and June 2022, where the incidence of xylazine in fentanyl-related deaths grew by an astonishing 276% across 20 states and the District of Columbia. Chillingly, from 1999 to 2018, overdose deaths among young people that involved multiple substances surpassed those involving opioids alone, reflecting a growing complexity in substance use issues.
Addressing these stark realities is critical, as they underscore the urgent need for comprehensive treatment options for individuals struggling with substance use disorders. Although medications for opioid use disorder, such as methadone, buprenorphine, and naltrexone, have been proven effective in reducing death rates, fewer than 20% of those in need receive such medications. Similarly, approved medications for alcohol use disorder are underutilized, with only a small percentage of the nearly 28 million individuals affected receiving treatment.
To enhance access to these lifesaving medications, policymakers can take immediate action by dismantling unnecessary hurdles for both patients and healthcare providers. Reducing regulatory barriers for prescriptions, aligning state regulations with federal standards, and minimizing counseling and daily visit requirements for treatments like methadone can significantly expand access to care. Additionally, prohibiting prior authorization hurdles imposed by Medicaid and insurance companies will help more individuals obtain the treatments they require.
Moreover, Medicaid managed care organizations should be mandated to include all FDA-approved medications for alcohol use disorder in their coverage plans, as current practices fall short, with less than half of plans offering comprehensive drug coverage. Varied financial models may reflect the potential for improvements in access. For instance, Massachusetts utilizes a combination of block grants and Medicaid funds to support treatment facilities, while Michigan’s health home model emphasizes tailored payments to meet individual patient needs.
Unfortunately, no FDA-approved medications are available to treat stimulant use disorders. However, effective strategies such as contingency management can make a difference. This approach rewards positive behavioral changes with monetary incentives, validated through clean urine tests. While some facilities, such as the Veterans Health Administration, have used this method successfully since 2011, it remains significantly underutilized nationwide.
States have various options to financially support contingency management treatments. By leveraging Section 1115 Medicaid waivers, several states have created avenues to fund this kind of service, utilizing federal and state resources to ensure broader access. Expanding the use of such innovative funding strategies could further reduce the impact of polysubstance overdoses.
Further, implementing overdose prevention tools represents another vital strategy to combat rising fatalities. Policymakers should advocate for increased access to naloxone, a medication that reverses opioid overdoses. By promoting community programs that facilitate naloxone training and distribution, especially in settings like hospitals and treatment facilities, states can greatly enhance their overdose response networks.
States should also endorse drug checking initiatives, allowing individuals to confirm the contents of their substances. Such programs help reduce the likelihood of dangerous combinations and empower users with knowledge about their drugs. Legislation that facilitates the use of drug checking equipment could greatly enhance public safety and prevent overdoses.
Additionally, customizing strategies to address the needs of vulnerable populations is essential. Groups such as LGBTQ+ individuals and racial minorities are disproportionately impacted by substance use issues and overdose deaths. Tailoring interventions that address these disparities will be crucial in mitigating the ongoing crisis.
As the landscape of substance use continues to change, reducing polysubstance-related deaths remains a critical national priority. By expanding treatment access and implementing comprehensive prevention strategies, lifesaving interventions can alter the grim trajectory of overdose fatalities in the United States.